Rapid Micro Biosystems to Announce Second Quarter 2022 Financial Results on August 12, 2022
Rapid Micro Biosystems (Nasdaq: RPID) is set to release its second quarter 2022 financial results on August 12, prior to market open. A management webcast will follow at 8:30 a.m. EST, accessible on the Company’s website. The Company specializes in automation solutions for healthcare product manufacturing, enhancing microbial quality control testing through its flagship Growth Direct System. This innovation improves efficiency, accuracy, and compliance, supporting the safe production of biologics, vaccines, and therapies.
- Announcement of second quarter 2022 financial results may indicate continued business operations.
- Growth Direct System enhances operational efficiency and compliance for healthcare manufacturing.
- None.
LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2022 financial results on Friday, August 12, prior to the market open.
In conjunction with the release, the Company’s management team will host a webcast conference call at 8:30 a.m. EST on Friday, August 12, 2022. The live and archived webcast is accessible on the Company’s website here and will be available for replay for one year.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
FAQ
When will Rapid Micro Biosystems release Q2 2022 financial results?
What time is the webcast for the Q2 2022 results?
What technology does Rapid Micro Biosystems focus on?
What is the Growth Direct System?
